7/17/2014

BioTheranostics has received the go-ahead to distribute its Breast Cancer Index in New York. The molecular diagnostic assay measures a patient's risk of recurrent estrogen receptor-positive breast cancer and determines whether extended endocrine treatment will benefit the patient.

Related Summaries